Pharmaceutical and healthcare information provider
IMS Health, US, has announced a multi-year partnership with US based oncology information provider,
IntrinsiQ Research, to support the industry's rising need for comprehensive, global insights into cancer treatments. Under the deal, IMS will integrate IntrinsiQ's US-based anonymized patient-level oncology information into its multi-country oncology offering. The company's oncology market intelligence and consulting capabilities now span the US, UK, Germany, France, Italy, Japan and Spain.
The integration of IntrinsiQ data with IMS Oncology Analyzer creates one of the largest commercially available oncology repositories for cancer treatment insights. Also, the combination of IntrinsiQ's oncology data with other IMS core information assets will initiate expanded product and consulting capabilities that support client needs across the entire oncology product lifecycle. IMS's core information assets include anonymized patient level data as well as global sales and prescription insights.
IntrinsiQ's oncology database is expected to augment IMS's global offerings with clinically rich information captured at the point of care. The database features data on 80 tumor types and over 13,000 unique, anonymized patient records updated monthly. The company's clinical dosing software, IntelliDose, comprises more than five million administrations of drug therapy and 36 months of history available for in-depth analysis.
Click here to read the original press release.